NeoGenomics, Inc. Expands Investor Relations Program
FORT MYERS, Fla., May 25 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services nationwide, announced today that it has increased the scope of its investor relations program with Hawk Associates. Beginning today, NeoGenomics will be featured for investor awareness and information on the Hawk Associates website, http://www.hawkassociates.com , in addition to the American Microcap Institute website, http://www.americanmicrocaps.com .
Hawk Associates will provide additional services for the company, including a virtual investor relations kit, e-mail alerts about news from the company, regular company profile updates, assistance with quarterly conference calls, and press release support. Hawk will also handle investor queries for the company.
Frank Hawkins, CEO of Hawk Associates, said, "We are pleased that NeoGenomics has expanded its investor relations program. The company recently reported its first profitable quarterly results and has completed an accretive acquisition of a lab centrally located in Nashville, TN. We look forward to working closely with this energetic young company to help tell its story to investors."
Robert Gasparini, president of NeoGenomics, said, "We have grown to the point where it is important to have a full-service investor relations firm available to help us communicate effectively with our shareholders while the management team concentrates on executing our strategy for growth. Hawk Associates has done an excellent job in articulating the investment thesis for NeoGenomics through their 37 page in-depth equity research report, which they published through their American Microcap Institute subsidiary. We plan to build upon this effort through the state-of-the-art Hawk website that also offers a virtual investor kit for 24/7 access by investors. We encourage investors to take advantage of Hawk's e-mail alert system."
Information for investors, including a profile of NeoGenomics and the subscription form for free NeoGenomics e-mail alert notifications can be obtained by visiting http://www.hawkassociates.com or http://www.americanmicrocaps.com . Interested parties can also access an in- depth equity research report from the American Microcap Institute at http://www.americanmicrocapinstitute.com/ngnm .
About NeoGenomics, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that offers cancer genetic diagnostic testing services including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry and molecular genetic testing. NeoGenomics is headquartered in Fort Myers, Fla., and services the needs of oncologists, pathologists, urologists, hospitals and other reference laboratories not offering genetic testing throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.org .
An online investor kit including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com and http://www.americanmicrocaps.com. For investor relations questions regarding NeoGenomics, contact Frank Hawkins or Julie Marshall, Hawk Associates, at (305) 451-1888, e-mail: info@hawkassociates.com .
About Hawk Associates, Inc.
Hawk Associates, Inc. is a full-service national investor relations and financial media relations consulting firm serving clients nationwide and in Canada. For more information about Hawk Associates, visit http://www.hawkassociates.com or contact Frank Hawkins or Julie Marshall at (305) 451-1888, email: info@hawkassociates.com .
Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, including, but not limited to, any adverse effect or limitations caused by governmental regulations, the company's ability to attract and retain qualified personnel, to initiate and develop client relationships, to gain market acceptance of service offerings, as well as other risks described from time to time in the company's filings with the Securities and Exchange Commission. Although the company has used its best efforts to be accurate in making those forward-looking statements, there can be no assurance that the assumptions made by management will materialize. In addition, the information set forth in the company's Form 10-KSB for the fiscal year ended December 31, 2005 describe certain additional risks and uncertainties that could cause actual results to vary materially from the future results covered in such forward-looking statements. The company undertakes no obligation to publicly revise or update the forward-looking statements to reflect new information, subsequent events or otherwise.
NeoGenomics, Inc.CONTACT: Steven C. Jones, Director of Investor Relations, NeoGenomics,+1-239-598-0964, or sjones@neogenomics.org; or Frank N. Hawkins or JulieMarshall, both of Hawk Associates, Inc., +1-305-451-1888, orinfo@hawkassociates.com, for NeoGenomics